Share：
Share this content in WeChat
X
[Chinese][PDF]728109
• Review •
Research progress on proton magnetic resonance spectroscopic imaging for monitoring response of neoadjuvant chemotherapy in breast cancer
ZHANG Ren-zhi  ZHOU Chun-wu 

DOI:10.3969/j.issn.1674-8034.2012.02.013.


[Abstract] MR multi-functional imaging techniques, such as MR perfusion weighted imaging, diffusion weighted imaging and spectroscopic imaging, have a important value in breast cancer diagnosis, differential diagnosis and monitoring therapeutic effect of neoadjuvant chemotherapy for breast cancer. This paper is devoted to reviewing the proton-magnetic resonance spectroscopic (1HMRS ) imaging techniques. The basic principle of 1HMRS, commonly used positioning technology and spectral line postprocessing are intruoduced essentially. Present status and progress of the application on 1HMRS in breast cancer diagnosis, differential diagnosis and monitoring therapeutic effect of neoadjuvant chemotherapy for breast cancer are introduced in detail.
[Keywords] Magnetic resonance imaging；Magnetic resonance spectroscopy；Breast cancer；Neoadjuvant chemotherapy

ZHANG Ren-zhi Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

ZHOU Chun-wu * Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China

*Correspondence to: Zhou CW, cjr.zhouchunwu@vip.163.com

Conflicts of interest   None.

Received  2011-02-24
Accepted  2012-01-04
DOI: 10.3969/j.issn.1674-8034.2012.02.013
DOI:10.3969/j.issn.1674-8034.2012.02.013.

[1]
Maur M, Guarneri V, Frassoldati A, et al. Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. Ann Oncology, 2006, 17(suppl 5): v158-v164.
[2]
Sachelarie I, Grossbard ML, Chadha M, et al. Primary systemic therapy of breast cancer. Oncologist, 2006, 11(6): 574-589.
[3]
Vanessa N, Scott I, David E, et al. Use of new imaging technique to predict tumor response to therapy. Lancet Oncol, 2010, 11(1): 92-102.
[4]
Sliverstein MJ, Lagios MD, Recht A, et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg, 2005, 201(4): 586-589.
[5]
Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping tomonitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 2007, 25(1): 1-13.
[6]
Seqara D, Krop IE, Garber JE, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol, 2007, 96(6): 474-480.
[7]
Baek HM, Chen JH, Nie K, et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology, 2009, 10(1): 1148-1153.
[8]
Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res, 2007, 13(2pt 1): 443-450.
[9]
Park MJ, Cha ES, Kang BJ, et al. The role of diffusion-weighted imaging and the apparent diffusion (ADC) values for breast tumors. Korean J Radio, 2007, 8(5): 390-396.
[10]
Danishad KK, Sharma U, Sah RG, et al. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy(NACT) monitored using sequential magnetic resonance spectroscopic imaging(MRSI). NMR Biomed, 2010, 23(3): 233-241.
[11]
Hu J, Vartanian SA, Xuan Y, et al. An improved 1H magnetic resonance spectroscopic imaging technique for the human breast: preliminary result. Magn Reson Imaging, 2005, 23(2): 571-576.
[12]
Jacobs MA, Barker PB, Bottomley PA, et al. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging, 2004, 19(1): 68-75.
[13]
Huang W, Fisher PR, Dulaimy K, et al. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology, 2004, 232(2): 585-591.
[14]
郭绣琴，肖叶玉，沈智威, 等. 磁共振频谱数据定量后处理技术比较. 磁共振成像, 2010, 1(1): 126-129.
[15]
Stanwell P, Gluch L, Clark D,et al. Specificity of choline metabolites for in vivo diagnosis of brest cancer using 1H MRS at 1.5T. Eur Radiol, 2005, 236(1): 465-475.
[16]
Katz- Brull, Lavin PT, Lenkinski RE, et al. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst, 2002, 94(16): 1197-1203.
[17]
Bartella L, Thakur S, Morris E, et al. Enhancing nonmass lesion in the breast: evaluation with (1H)MR spectroscopy. Radiology, 2007, 245(1): 80-87.
[18]
Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroacopy and its response to neoaduvnt chemotheapy in locally advanced breast cancer. Br J Cancer, 2001, 84(8): 1016-1022.
[19]
Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat, 2003, 78(1): 51-58.
[20]
Bartella L, Huang W. Proton (1H) MR spectroscopy of the breast. Radiograghics, 2007, 27(suppl 1): S241-S252.
[21]
Katz-Brull R, Lavin PT, Lenkinski RE, et al. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesion. J Natl Cancer, 2002, 94(16): 1197-1203.
[22]
Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)HMR spectroscopy-a pilot study at 4T. Radiology, 2004, 233(2): 424-431.
[23]
Lenkinski RE, Wang X, Elian M, et al. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med, 2009, 61(6): 1286-1292.
[24]
Mountford C, Ramadan S, Stanwell P, et al. Proton MRS of the breast in the clinical setting. NMR in biomedicine, 2009, 22(1): 54-64.
[25]
Sharma U, Kumar M, Sah RG, et al. Study of normal breast tissue by in vivo volume localized proton MR spectroscopy: variation of water-fat ratio in relation to the heterogeneity of the breast and the menstrual cycle. Magn Reson Imaging, 2009, 27(6): 785-791.

PREV Evaluation Methodology of MRI SNR
NEXT Axillary Kimura,s disease with ipsilateral breast fibroadenoma misdiagnosed as breast carcinoma: A case report
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn